798 reports of this reaction
5.0% of all ERTAPENEM SODIUM reports
#2 most reported adverse reaction
MACULAR DEGENERATION is the #2 most commonly reported adverse reaction for ERTAPENEM SODIUM. There are 798 FDA adverse event reports linking ERTAPENEM SODIUM to MACULAR DEGENERATION. This represents approximately 5.0% of all 15,826 adverse event reports for this drug.
Patients taking ERTAPENEM SODIUM who experience macular degeneration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MACULAR DEGENERATION is moderately reported among ERTAPENEM SODIUM users, representing a notable but not dominant share of adverse events.
In addition to macular degeneration, the following adverse reactions have been reported for ERTAPENEM SODIUM:
The following drugs have also been linked to macular degeneration in FDA adverse event reports:
MACULAR DEGENERATION has been reported as an adverse event in 798 FDA reports for ERTAPENEM SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
MACULAR DEGENERATION accounts for approximately 5.0% of all adverse event reports for ERTAPENEM SODIUM, making it one of the most commonly reported side effect.
If you experience macular degeneration while taking ERTAPENEM SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.